EUVIMEDEUVIMED entdecken
Crossref

Yuzhuo Zhixiao pill can treat non-alcoholic steatohepatitis through modulation of gut microbiota, bile acid and short-chain fatty acid metabolism

Yuanqin Du, Jian Xu, Juhong Jia, Yaobin Nong, Yong Lin, Yixian Ye, Yuexue Zhong, Qinwen Tan, Yanfei Wei, Guihua Huang, Dewen Mao, Guochu Huang und 4 weitere

Phytomedicine · 2025

DOI: 10.1016/j.phymed.2025.157348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2025. Verfasst von Yuanqin Du und 15 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi University of Chinese Medicine, Nanning, 530200, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Non-alcoholic Fatty Liver Disease, Drugs, Chinese Herbal, Fatty Acids, Volatile. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China, Guangxi University of Chinese Medicine, Guangxi Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Yuzhuo Zhixiao Pill (YZZXP), a formulation in traditional Chinese medicine (TCM), exhibits therapeutic potential in non-alcoholic steatohepatitis (NASH). However, the mechanisms underlying its effects, particularly those involving gut microbiota-bile acid-short-chain fatty acid (GM-BA-SCFA) interactions, remain unclear. Current therapies present notable side effects and inadequately address the multifactorial etiology of NASH. PURPOSE: To evaluate the anti-NASH efficacy of YZZXP and elucidate its mechanism, focusing on GM remodeling and BA/SCFA regulation. STUDY DESIGN: This study established a NASH model in rats using a high-fat diet (HFD) and performed fecal microbiota transplantation (FMT) experiments. METHODS: The therapeutic impacts of YZZXP on gut microbial structure (16S rDNA sequencing), SCFA concentrations, and BA profiles (analyzed by LC-MS and GC-MS) were assessed. RESULTS: YZZXP administration alleviated HFD-induced obesity, hepatic steatosis, inflammatory responses, and disturbances in glycolipid metabolism. Microbial profiling via 16S rDNA sequencing revealed restored gut microbial diversity, marked by increased Akkermansia, Bacteroides, and Roseburia abundance. PROB and FMT interventions validated GM modulation as central to YZZXP 's effects. Targeted metabolomic analyses demonstrated elevated levels of SCFAs (notably butyrate and acetate) and substantial shifts in BA composition, accompanied by downregulation of intestinal FXR-FGF19 signaling and enhanced cholesterol excretion. CONCLUSIONS: YZZXP exerts anti-NASH activity through a synergistic mechanism comprising GM restoration, BA metabolic reprogramming via FXR pathway inhibition, and SCFA-driven metabolic modulation. In contrast to monotherapy approaches, the multi-target strategy of YZZXP prevents compensatory dysbiosis and yields more durable metabolic benefits than PROB or FMT alone. By integrating microbiota-metabolite interplay into therapeutic design, YZZXP introduces a novel paradigm in traditional medicine for NASH management, addressing the limitations of synthetic agents while promoting metabolic homeostasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeNon-alcoholic Fatty Liver DiseaseDrugs, Chinese HerbalFatty Acids, VolatileBile Acids and SaltsAnimalsMaleRats, Sprague-DawleyDiet, High-FatRatsFecal Microbiota TransplantationDisease Models, AnimalLiver

Stichwörter der Autor:innen

BAGut microbiotaNASHSCFAYZZXP

Substanzen

Drugs, Chinese HerbalFatty Acids, VolatileBile Acids and Salts

Autor:innen und Institutionen

  • Guangxi University of Chinese Medicine, Nanning, 530200, China.
  • Nanning Traditional Chinese Medicine Hospital, Nanning, 530028, China.
  • Guangxi University of Chinese Medicine, Nanning, 530200, China; Guangxi Key Laboratory of Translational Medicine for Treating High-Incidence Infectious Diseases with Integrative Medicine, Nanning, 530200, China.
  • The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, China.
  • The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, China. Electronic address: 18776985262@163.com.
  • The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, China; Guangxi Key Laboratory of Translational Medicine for Treating High-Incidence Infectious Diseases with Integrative Medicine…

Förderung

  • Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China
  • Guangxi University of Chinese Medicine
  • Guangxi Natural Science Foundation

Zitieren

APA

Du, Y., Xu, J., Jia, J., Nong, Y., Lin, Y., Ye, Y., Zhong, Y., Tan, Q., Wei, Y., Huang, G., Mao, D., Huang, G., Lu, L., Peng, Y., Huang, H., & Huang, J. (2025). Yuzhuo Zhixiao pill can treat non-alcoholic steatohepatitis through modulation of gut microbiota, bile acid and short-chain fatty acid metabolism. Phytomedicine. https://doi.org/10.1016/j.phymed.2025.157348

Vancouver

Du Y, Xu J, Jia J, Nong Y, Lin Y, Ye Y, et al. Yuzhuo Zhixiao pill can treat non-alcoholic steatohepatitis through modulation of gut microbiota, bile acid and short-chain fatty acid metabolism. Phytomedicine. 2025. doi:10.1016/j.phymed.2025.157348

BibTeX
@article{Du2025,
  author = {Du, Yuanqin and Xu, Jian and Jia, Juhong and Nong, Yaobin and Lin, Yong and Ye, Yixian and Zhong, Yuexue and Tan, Qinwen and Wei, Yanfei and Huang, Guihua and Mao, Dewen and Huang, Guochu and Lu, Lu and Peng, Yujiao and Huang, Hongna and Huang, Jingjing},
  title = {Yuzhuo Zhixiao pill can treat non-alcoholic steatohepatitis through modulation of gut microbiota, bile acid and short-chain fatty acid metabolism},
  journal = {Phytomedicine},
  year = {2025},
  doi = {10.1016/j.phymed.2025.157348}
}
Kostenlos starten →